Harrow Appoints Frank Mullery as CEO, Bridseida Cruz as Head of Quality at ImprimisRx Subsidiary

Published on October 7, 2025
NASHVILLE, Tenn.—Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, has announced leadership changes at its wholly-owned subsidiary, ImprimisRx. According to the announcement, Frank Mullery has been appointed as chief executive officer (CEO) and Bridseida Cruz has been named as head of quality. ImprimisRx is an ophthalmic pharmacy specializing in custom medications for eyecare professionals.
Continue reading on website
Other news

Monthly pipeline update: A September news roundup | Optometry Times - Clinical News

October 6, 2025
The latest in drug and technology developments and updates from September 2025.

New questionnaire may be useful for assessing quality of life in patients with vision-degrading floaters | Optometry Times - Clinical News

October 7, 2025
The National Eye Institute Visual Function Questionnaire was a tool that has been used previously to assess the patient-reported vision-related quality of life in patients with floaters.